You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

elyxyb Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Elyxyb, and when can generic versions of Elyxyb launch?

Elyxyb is a drug marketed by Scilex Pharms and is included in one NDA. There are six patents protecting this drug.

This drug has twenty-five patent family members in twelve countries.

The generic ingredient in ELYXYB is celecoxib. There are twenty-six drug master file entries for this compound. Sixty-four suppliers are listed for this compound. Additional details are available on the celecoxib profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Elyxyb

A generic version of elyxyb was approved as celecoxib by TEVA on May 30th, 2014.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for elyxyb?
  • What are the global sales for elyxyb?
  • What is Average Wholesale Price for elyxyb?
Summary for elyxyb
International Patents:25
US Patents:6
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 2
Raw Ingredient (Bulk) Api Vendors: 175
Patent Applications: 4,546
Drug Prices: Drug price information for elyxyb
What excipients (inactive ingredients) are in elyxyb?elyxyb excipients list
DailyMed Link:elyxyb at DailyMed
Drug patent expirations by year for elyxyb
Drug Prices for elyxyb

See drug prices for elyxyb

Pharmacology for elyxyb

US Patents and Regulatory Information for elyxyb

elyxyb is protected by six US patents.

Patents protecting elyxyb

Oral composition of celecoxib for treatment of pain
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS

Oral composition of celecoxib for treatment of pain
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS

Oral composition of celecoxib for treatment of pain
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS

Oral composition of celecoxib for treatment of pain
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS

Oral composition of celecoxib for treatment of pain
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS

Oral composition of celecoxib for treatment of pain
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Scilex Pharms ELYXYB celecoxib SOLUTION;ORAL 212157-001 May 5, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Scilex Pharms ELYXYB celecoxib SOLUTION;ORAL 212157-001 May 5, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Scilex Pharms ELYXYB celecoxib SOLUTION;ORAL 212157-001 May 5, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Scilex Pharms ELYXYB celecoxib SOLUTION;ORAL 212157-001 May 5, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Scilex Pharms ELYXYB celecoxib SOLUTION;ORAL 212157-001 May 5, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for elyxyb

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Pfizer Limited Onsenal celecoxib EMEA/H/C/000466
Onsenal is indicated for the reduction of the number of adenomatous intestinal polyps in familial adenomatous polyposis (FAP), as an adjunct to surgery and further endoscopic surveillance (see section 4.4).The effect of Onsenal-induced reduction of polyp burden on the risk of intestinal cancer has not been demonstrated (see sections 4.4 and 5.1)
Withdrawn no no no 2003-10-17
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for elyxyb

See the table below for patents covering elyxyb around the world.

Country Patent Number Title Estimated Expiration
South Korea 101994129 ⤷  Sign Up
World Intellectual Property Organization (WIPO) 2017208069 ⤷  Sign Up
Russian Federation 2745196 ПЕРОРАЛЬНАЯ КОМПОЗИЦИЯ ЦЕЛЕКОКСИБА ДЛЯ ЛЕЧЕНИЯ БОЛИ (ORAL CELECOXIB COMPOSITION FOR PAIN TREATMENT) ⤷  Sign Up
Russian Federation 2708254 Пероральная композиция целекоксиба для лечения боли (ORAL CELECOXIB COMPOSITION FOR TREATING PAIN) ⤷  Sign Up
World Intellectual Property Organization (WIPO) 2016191744 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for elyxyb

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0731795 10075033 Germany ⤷  Sign Up PRODUCT NAME: CELECOXIB; NAT. REGISTRATION NO/DATE: 48802.00.00 20000518; FIRST REGISTRATION: SE 14838 19991203
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.